Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL. Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 150. 2015 Authors' objectives We conducted a systematic review to examine the long-term consequences of discontinuing disease-modifying treatment (DMT) for multiple sclerosis (MS) by examining the long-term benefits and harms, and the reasons for discontinuing treatment. We also examined the evidence for people's values, beliefs, and preferences regarding discontinuing DMT. Authors' conclusions MS patients and providers have little information to guide decisions to discontinue DMT. Indexing Status Subject indexing assigned by NLM MeSH Adult; Cost Savings; Cost-Benefit Analysis; Disability Evaluation; Drug Administration Schedule; Drug Costs; Guideline Adherences; Immunosuppressive Agents /administration & Ireland /epidemiology; Medical Futility; Middle Aged; Multiple Sclerosis, Chronic Progressive /diagnosis /drug therapy /economics /epidemiology; Neurology /economics; Practice Guidelines as Topic; Practice Patterns, Physicians' /economics; Rural Health Services; Severity of Illness Index; Surveys and Questionnaires; Treatment Failure; Urban Health Services; dosage /economics Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAP@ahrq.hhs.gov AccessionNumber 32015000565 Date abstract record published 21/05/2015 |